Yoon Koo Kang

Summary

Affiliation: University of Ulsan
Country: Korea

Publications

  1. doi request reprint A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic ro 43 gil, Songpa Gu, Seoul, 138 736, South Korea
    Invest New Drugs 32:355-61. 2014
  2. doi request reprint Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)
    Yoon Koo Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic ro 43 gil, Songpa Gu, Seoul, 138 736, Korea
    Cancer Chemother Pharmacol 73:139-49. 2014
  3. doi request reprint Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Yoon Koo Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Electronic address
    Lancet Oncol 14:1175-82. 2013
  4. pmc Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
    Y K Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic ro 43 gil, Songpa Gu, Seoul 138 736, Korea
    Br J Cancer 108:1245-51. 2013
  5. doi request reprint Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Cancer Chemother Pharmacol 71:43-51. 2013
  6. pmc Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
    H J Kang
    Division of Oncology, Department of Medicine, Asan Medical Center, 388 1 Pungnap dong, Songpa Gu, Seoul 138 736, South Korea
    Br J Cancer 92:246-51. 2005
  7. ncbi request reprint [Prediction of malignant potential of gastrointestinal stromal tumors]
    Yoon Koo Kang
    Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
    Korean J Gastroenterol 43:380-2. 2004
  8. doi request reprint Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Y K Kang
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, Songpa Gu, Seoul, Republic of Korea
    Ann Oncol 20:666-73. 2009
  9. doi request reprint Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Songpa Gu, Seoul, 138 736 Korea
    J Clin Oncol 28:3824-9. 2010
  10. doi request reprint Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors
    Tae Won Kim
    Section of Oncology, Department of Medicine, Asan Medical Center, 388 1 Poongnap dong, Songpa Ku, Seoul, Korea
    Oncologist 14:540-7. 2009

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. doi request reprint A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic ro 43 gil, Songpa Gu, Seoul, 138 736, South Korea
    Invest New Drugs 32:355-61. 2014
    ..Conclusion Tivantinib as a monotherapy showed a modest efficacy in previously treated MGC, and further studies taking account of predictive biomarkers and/or combination with other chemotherapy may be needed in MGC. ..
  2. doi request reprint Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)
    Yoon Koo Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic ro 43 gil, Songpa Gu, Seoul, 138 736, Korea
    Cancer Chemother Pharmacol 73:139-49. 2014
    ..To improve the efficacy of adjuvant chemotherapy with mitomycin-C and fluoropyrimidine (Mf) in gastric cancer, we designed a new regimen (iceMFP) and investigated in a phase III study...
  3. doi request reprint Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Yoon Koo Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Electronic address
    Lancet Oncol 14:1175-82. 2013
    ..We aimed to assess efficacy of imatinib rechallenge in these patients...
  4. pmc Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
    Y K Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic ro 43 gil, Songpa Gu, Seoul 138 736, Korea
    Br J Cancer 108:1245-51. 2013
    ..This phase 3 study evaluated the efficacy of new adjuvant chemotherapy (MFP), which intensified the mitomycin-C (MMC) plus short-term doxifluridine (Mf) for gastric cancer...
  5. doi request reprint Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Cancer Chemother Pharmacol 71:43-51. 2013
    ..To evaluate the efficacy and safety of 2-year adjuvant imatinib for patients at high risk of recurrence after complete resection of localized gastrointestinal stromal tumor with KIT exon 11 mutation...
  6. pmc Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
    H J Kang
    Division of Oncology, Department of Medicine, Asan Medical Center, 388 1 Pungnap dong, Songpa Gu, Seoul 138 736, South Korea
    Br J Cancer 92:246-51. 2005
    ..Capecitabine in combination with cisplatin was effective and well tolerated as first-line treatment in patients with recurrent gastric cancer after fluoropyrimidine-based adjuvant chemotherapy...
  7. ncbi request reprint [Prediction of malignant potential of gastrointestinal stromal tumors]
    Yoon Koo Kang
    Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
    Korean J Gastroenterol 43:380-2. 2004
  8. doi request reprint Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Y K Kang
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, Songpa Gu, Seoul, Republic of Korea
    Ann Oncol 20:666-73. 2009
    ..To compare capecitabine/cisplatin with 5-fluorouracil/cisplatin as first-line treatment for advanced gastric cancer (AGC)...
  9. doi request reprint Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Songpa Gu, Seoul, 138 736 Korea
    J Clin Oncol 28:3824-9. 2010
    ..To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine...
  10. doi request reprint Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors
    Tae Won Kim
    Section of Oncology, Department of Medicine, Asan Medical Center, 388 1 Poongnap dong, Songpa Ku, Seoul, Korea
    Oncologist 14:540-7. 2009
    ..This study analyzed the relationship between treatment outcome and kinase mutational status in Korean patients with advanced gastrointestinal stromal tumors (GISTs)...
  11. doi request reprint Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer
    Yoon Koo Kang
    Department of Oncology, Asan Medical Center, 86 Asanbyeongwon gil, Songpa Gu, Seoul 138 736, South Korea
    Cancer Chemother Pharmacol 67:1435-43. 2011
    ..This study was conducted to determine the optimal dosage of the docetaxel-capecitabine-cisplatin (DXP) regimen and to evaluate its efficacy and safety in patients with advanced gastric cancer...
  12. ncbi request reprint Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron
    Y K Kang
    Department of Internal Medicine, Korea Cancer Centre Hospital, Seoul, Korea
    J Int Med Res 30:220-9. 2002
    ..Ramosetron and granisetron appear to have equivalent efficacy and tolerability profiles, but the effects of ramosetron on the prevention of acute vomiting in patients undergoing cisplatin chemotherapy were longer lasting...
  13. pmc Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea
    Yoon Koo Kang
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Korean Med Sci 25:1543-52. 2010
    ..We hope the guideline can be of help in enhancing the quality of diagnosis by members of the Korean associate of physicians involving in GIST patients's care and subsequently in achieving optimal efficacy of treatment...
  14. doi request reprint Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
    Dok Hyun Yoon
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 86 Asanbyeongwon gil, Songpa Gu, Seoul 138 736, Korea
    Invest New Drugs 30:819-27. 2012
    ..To assess the efficacy and safety of sunitinib with regards to primary genotypes of tumor in Korean patients with advanced gastrointestinal stromal tumors (GISTs) who failed an initial therapy of imatinib...
  15. doi request reprint Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer
    Inkeun Park
    Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Poongnap dong, Songpa Gu, Seoul, 138 736, Korea
    Cancer Chemother Pharmacol 65:473-80. 2010
    ....
  16. ncbi request reprint A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy
    Jae Lyun Lee
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, South Korea
    Cancer Chemother Pharmacol 61:631-7. 2008
    ..Docetaxel has shown promising activity against this disease. In this study, we explored the efficacy and safety of docetaxel monotherapy as salvage chemotherapy in AGC after F and P combination chemotherapy failed...
  17. ncbi request reprint Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer
    Jin Hee Ahn
    Section of Hematology Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 138 736, Korea
    Cancer Chemother Pharmacol 50:104-10. 2002
    ..Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin. This study was designed to evaluate the nephrotoxicity of heptaplatin in comparison with that of cisplatin...
  18. doi request reprint Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer
    Sun Jin Sym
    Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Pungnap 2 dong, Songpa Gu, Seoul, 138 736, Korea
    Cancer Chemother Pharmacol 66:373-80. 2010
    ....
  19. doi request reprint Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)
    Sun Jin Sym
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Surg Oncol 98:27-33. 2008
    ..We investigated the role of surgical intervention for advanced GIST after imatinib...
  20. doi request reprint Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor
    Inkeun Park
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Poongnap 2dong, Songpa Gu, Seoul 138 736, Republic of Korea
    Jpn J Clin Oncol 39:105-10. 2009
    ..We evaluated the results of imatinib dose escalation in patients with advanced gastrointestinal stromal tumors (GISTs) after disease progression on standard-dose imatinib...
  21. ncbi request reprint Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report
    Jung Hee Lee
    Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
    J Clin Oncol 20:1751-8. 2002
    ..We conducted a prospective randomized trial to define the optimal sequence of chemotherapy and radiotherapy of postoperative adjuvant treatment in stage II and III rectal cancer...
  22. doi request reprint Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability
    Kyu pyo Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Cancer Chemother Pharmacol 68:285-91. 2011
    ....
  23. doi request reprint Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Chul Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Gu, Seoul 138 736, South Korea
    Invest New Drugs 30:306-15. 2012
    ..To define maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary efficacy of sorafenib plus capecitabine/cisplatin in advanced gastric cancer (AGC) patients...
  24. ncbi request reprint Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1
    Jae Lyun Lee
    Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388 1 Poongnap dong, Songpa Gu, 138 736, Seoul, Korea
    Dig Dis Sci 51:1043-6. 2006
  25. doi request reprint Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer
    Sun Jin Sym
    Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Ann Surg Oncol 17:1024-32. 2010
    ..This phase II study was conducted to evaluate the efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and capecitabine (DXP) in patients with unresectable locally advanced and/or intra-abdominal metastatic gastric cancers...
  26. doi request reprint Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis
    Jae Cheol Jo
    Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388 1 Poongnap 2dong, Songpa Gu, Seoul 138 736, South Korea
    Jpn J Clin Oncol 37:936-41. 2007
    ..To investigate the efficacy and safety of docetaxel monotherapy as salvage chemotherapy for advanced gastric cancer (AGC) in clinical practice and to determine the prognostic factors in these patients...
  27. doi request reprint A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group
    Yong Sang Hong
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul Department of Internal Medicine, Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul Department of Internal Medicine, Samsung Medical Center, Division of Hematology Oncology, Sungkyunkwan University School of Medicine, Seoul Center for Colorectal Cancer, National Cancer Center, Research Institute and Hospital, Goyang Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
    Am J Clin Oncol 37:19-23. 2014
    ..We have investigated the efficacy and safety of bevacizumab plus capecitabine and oxaliplatin as first-line chemotherapy for Korean patients with mCRC...
  28. doi request reprint A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor
    Min Hee Ryu
    Department of Internal Medicine, Division of Oncology, Asan Medical Center, Songpa Gu, Seoul, Korea
    Oncology 76:326-32. 2009
    ..This prospective, multicenter, phase 2 study evaluated the efficacy and safety of imatinib mesylate and assessed KIT and PDGFRA gene mutation status in Korean patients with gastrointestinal stromal tumors (GISTs)...
  29. ncbi request reprint Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate
    Min Hee Ryu
    Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388 1, Poongnap dong, Songpa Gu, Seoul, Korea
    Jpn J Clin Oncol 36:17-24. 2006
    ..We evaluated and categorized the patterns of progression of metastatic or unresectable GIST treated with imatinib to identify the prognostic significance and contribution to further treatment decision-making...
  30. doi request reprint A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer
    Kyu pyo Kim
    Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Ku, Seoul 138 736, Korea
    Cancer Chemother Pharmacol 71:1609-17. 2013
    ..In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer...
  31. doi request reprint Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis
    Byung Woog Kang
    Section of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138 736, Korea
    Med Oncol 26:32-7. 2009
    ..The combination of bevacizumab plus FOLFIRI or FOLFOX showed modest activity and was relatively tolerable in patients with metastatic colorectal cancer refractory to both FOLFIRI and FOLFOX...
  32. ncbi request reprint Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis
    Sung Sook Lee
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Jpn J Clin Oncol 37:30-7. 2007
    ..In this study, we sought to evaluate the efficacy and feasibility of the XP combination for the treatment of AGC in clinical practice and to determine the prognostic factors affecting treatment outcomes...
  33. doi request reprint Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients
    Dong Hoe Koo
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Gu, Seoul, 138 736, Korea
    Gastric Cancer 15:305-12. 2012
    ..We therefore evaluated the efficacy and feasibility of a 3-week schedule of S-1 and cisplatin in patients with AGC, as well as assessing factors prognostic of patient outcomes...
  34. doi request reprint A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
    Sun Jin Sym
    Department of Medicine, Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, South Korea
    Cancer Chemother Pharmacol 63:1-8. 2008
    ..We have evaluated the efficacy and safety of the ID combination for AGC patients after failure of fluoropyrimidine- or platinum-based chemotherapy...
  35. doi request reprint Sorafenib for recurrent hepatocellular carcinoma after liver transplantation
    Dok Hyun Yoon
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Gu, Seoul 138 736, Korea
    Jpn J Clin Oncol 40:768-73. 2010
    ..The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined...
  36. doi request reprint Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study
    Hye Jin Kang
    Division of Hematology Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Acta Oncol 51:528-36. 2012
    ..To assess the efficacy of imatinib for different tumor genotypes in Korean patients with advanced gastrointestinal stromal tumors (GIST)...
  37. ncbi request reprint Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer
    Jae Lyun Lee
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, South Korea
    Cancer Chemother Pharmacol 61:837-45. 2008
    ....
  38. doi request reprint Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma
    Jeong Eun Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Oncology 82:119-25. 2012
    ..We applied a dose escalation scheme to increase patient compliance and avoid AEs...
  39. ncbi request reprint Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy
    Young Seol Heo
    Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Clin Pharmacol 44:1166-72. 2004
    ..Our results suggest that a combined treatment agent and a patient's susceptibility to chemotherapy-related toxicity may increase the risk of capecitabine-induced hand-foot syndrome...
  40. doi request reprint Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane
    Sun Jin Sym
    Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Am J Clin Oncol 31:151-6. 2008
    ....
  41. doi request reprint A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
    Chul Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, South Korea
    Invest New Drugs 29:366-73. 2011
    ..The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XELOX...
  42. doi request reprint PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors
    Heung Moon Chang
    Department of Internal Medicine, Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Oncology 74:88-95. 2008
    ..In this study, we evaluated the prevalence of PDGFRalpha mutations and corresponding protein expression in GISTs, to determine their usefulness in obtaining a prognosis...
  43. doi request reprint Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses
    Gwang Hyeon Choi
    Department of Gastroenterology, Asan Liver Center, Department of Biostatistics, Department of Oncology, Asan Liver Center, and Department of Radiology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Poongnap 2dong, Songpa Gu, Seoul 138 736, Korea
    Radiology 269:603-11. 2013
    ....
  44. doi request reprint Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Jeong Eun Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Gu, Seoul 138 736, Korea
    Cancer Chemother Pharmacol 68:1285-90. 2011
    ..We compared the efficacy and safety of sorafenib in patients with Child-Pugh (CP) class B and CP class A...
  45. ncbi request reprint Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response
    Jae Lyun Lee
    Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Songpa Gu, Seoul, 138 736, Korea
    Jpn J Clin Oncol 36:704-11. 2006
    ..We sought to evaluate the clinical outcome of imatinib interruption in GIST patients who had achieved stable disease (SD) or showed better response to imatinib therapy...
  46. ncbi request reprint Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin
    Jin Hee Ahn
    Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Am J Clin Oncol 26:98-102. 2003
    ..Toxicities in both groups were generally mild and reversible. This study shows that a combination of oral doxifluridine plus leucovorin can be active and safe as a first-line treatment for patients with metastatic CRC...
  47. ncbi request reprint Leptomeningeal carcinomatosis in gastric cancer
    Jae Lyun Lee
    Department of Medicine, Division of Oncology Hematology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
    J Neurooncol 66:167-74. 2004
    ..Multivariate analysis revealed that the administration of CSF chemotherapy was the independent prognostic factor for survival...
  48. pmc Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane
    Jin Hee Ahn
    Section of Hematology Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Korean Med Sci 19:547-53. 2004
    ..Other nonhematologic toxicities were minimal and manageable. In conclusion, the combination of capecitabine and vinorelbine was effective and well tolerated in MBC patients even after treatment with anthracyclines and taxanes...
  49. ncbi request reprint Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors
    Tae Won Kim
    Section of Oncology Hematology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Clin Cancer Res 10:3076-81. 2004
    ..Constitutive mutational activation of c-kit has been found to be associated with the pathogenesis of gastrointestinal stromal tumors (GISTs). The prognostic significance of c-kit mutations, however, is still controversial...
  50. doi request reprint Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence
    Ho Jung An
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Int J Radiat Oncol Biol Phys 84:73-80. 2012
    ..To investigate the outcomes of adjuvant chemotherapy (CT) or chemoradiotherapy (CRT) after simultaneous surgical resection in rectal cancer patients with liver metastases (LM)...
  51. doi request reprint A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity
    Yoon Hee Choi
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Oncology 82:290-7. 2012
    ..We also evaluated the association between UGT1A1 and CYP2A6 polymorphisms and clinical phenotypes...
  52. doi request reprint A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction
    Dok Hyun Yoon
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, 138 736, Korea
    Invest New Drugs 29:332-9. 2011
    ..Hepatic dysfunction (HD) is common in patients with biliary tract cancer. A phase I study was conducted to assess the effects of a 3 week treatment schedule in Asian patients with or without HD...
  53. doi request reprint A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer
    Yoon Hee Choi
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 388 1, Pungnap dong, Songpa Gu, Seoul, 138 736, South Korea
    Cancer Chemother Pharmacol 68:905-12. 2011
    ....
  54. ncbi request reprint Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Yeon Hee Park
    Division of Hematology and Oncology, Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, 139 706, South Korea
    Cancer Chemother Pharmacol 61:623-9. 2008
    ..We evaluated efficacy and safety of XELOX in previously untreated patients with AGC...
  55. doi request reprint Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib
    Changhoon Yoo
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Clin Oncol 28:1554-9. 2010
    ..We therefore have evaluated the correlation between imatinib C(min) and the clinical characteristics of patients with GIST...
  56. doi request reprint Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Myoung Joo Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Gu, Seoul, Korea
    Invest New Drugs 30:1607-13. 2012
    ..Retrospective analysis revealed that the efficacy of cetuximab was similar in mCRC patients negative (EGFR-) and positive for EGFR. However, the efficacy of cetuximab has not been assessed prospectively in EGFR- mCRC patients...
  57. ncbi request reprint Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum
    Heung Moon Chang
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul 138 736, Korea
    Jpn J Clin Oncol 35:251-5. 2005
    ..We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-fluorouracil and platinum...
  58. pmc Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients
    Shinkyo Yoon
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Korean Med Sci 28:1248-52. 2013
    ..Imatinib blood level testing may be a promising approach for fine-tuning imatinib dosage for better tolerability and optimal clinical outcomes in patients with advanced GIST. ..
  59. ncbi request reprint Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial
    Tae Won Kim
    Section of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Acta Oncol 44:230-5. 2005
    ..There were no treatment-related deaths. These results indicate that CAPIRI has comparable activity and tolerability to FOLFIRI as first-line treatment for advanced colorectal cancer...
  60. doi request reprint Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure
    Changhoon Yoo
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Songpa Gu, Seoul 138 736, Korea
    Invest New Drugs 30:1703-8. 2012
    ..Changes in imatinib C(min) were associated with changes in albumin concentration. Monitoring of imatinib C(min) only for concerns about time-dependent increases in imatinib clearance is not necessary...
  61. doi request reprint The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients
    Byeong Seok Sohn
    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Oncology 77:224-30. 2009
    ..This study evaluated the clinical relevance of KRAS and BRAF mutational status in 66 irinotecan-refrac- tory Korean metastatic colorectal cancer (mCRC) patients treated with cetuximab-plus-irinotecan-based chemotherapy...
  62. doi request reprint Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy
    Young Wha Koh
    Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Am J Surg Pathol 37:1022-9. 2013
    ..In addition, postoperative LN positivity and diffuse-type histology were independent poor prognostic factors for PFS and OS...
  63. ncbi request reprint Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer
    Jae Ho Jeong
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, Korea
    Cancer Chemother Pharmacol 70:523-9. 2012
    ..Adjuvant chemotherapy with S-1 was proven to be effective in Japanese patients with advanced gastric cancer curatively resected with D2 lymph node dissection...
  64. ncbi request reprint Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial
    Yung Jue Bang
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Jpn J Clin Oncol 32:248-54. 2002
    ..The aim of the present study was to confirm the efficacy and tolerability of docetaxel 75 mg/m(2) in a population of Korean patients with advanced gastric cancer...
  65. pmc A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Dong Hoe Koo
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Korean Med Sci 22:S98-S103. 2007
    ..3%), asthenia (22.6%), diarrhea (12.9%), and paronychial cracking (12.9%). The combination of cetuximab with FOLFIRI was effective and tolerable in colorectal cancer patients heavily pretreated with a number of chemotherapy regimens...
  66. doi request reprint A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models
    Dong Hoe Koo
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Cancer Chemother Pharmacol 68:913-21. 2011
    ..To make up for the limitations of previous prognostic models, we developed and validated a model in patients with metastatic or recurrent gastric adenocarcinoma (AGC), and to compare with previous models...
  67. ncbi request reprint Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines
    Jin Hee Ahn
    Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1, Poongnap dong, Songpa Gu, Seoul 138 736, Korea
    Breast 14:304-9. 2005
    ..In conclusion, our data show that docetaxel plus cisplatin is effective with the manageable toxicity profile in MBC patients previously treated with anthracyclines...
  68. ncbi request reprint Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
    Jong Gwang Kim
    Department of Hematology Oncology, Korea Cancer Center Hospital, Seoul, South Korea
    Cancer Chemother Pharmacol 61:301-7. 2008
    ..The present study evaluated baseline patient- or tumor-related prognostic factors in patients with advanced gastric adenocarcinoma...
  69. ncbi request reprint Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea
    Changhoon Yoo
    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Am J Hematol 82:821-3. 2007
    ..Our study demonstrates an association between OAL and Cp infection in Korea, suggesting that Cp plays a role as a causative antigen in Korean OAL patients...
  70. doi request reprint Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer
    Seong Joon Park
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Oncology 82:83-9. 2012
    ..This study investigated the clinical relevance of FcγR gene polymorphisms and KRAS status in iri-notecan-refractory mCRC patients treated with cetuximab...
  71. doi request reprint Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience
    Myoung Joo Kang
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    Eur J Cancer 48:492-500. 2012
    ..We therefore investigated the incidence of VTE and the clinical characteristics associated with VTE in AGC patients treated with systemic chemotherapy...
  72. doi request reprint Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up
    Tae Won Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Int J Radiat Oncol Biol Phys 81:1025-31. 2011
    ..To determine the optimal sequence of postoperative adjuvant chemotherapy and radiotherapy in patients with Stage II or III rectal cancer...
  73. doi request reprint Predictors of recurrence after resection of small gastric gastrointestinal stromal tumors of 5 cm or less
    Mi Young Kim
    Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Asan Digestive Disease Research Institute, Seoul, Korea
    J Clin Gastroenterol 46:130-7. 2012
    ..To evaluate the recurrence predicting factors of small gastric gastrointestinal stromal tumors (GISTs) through the long-term follow-up after surgical/endoscopic resection...
  74. doi request reprint Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Young Soo Park
    Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon gil, Pungnap 2 dong, Songpa Gu 138 736, Seoul, Republic of Korea
    Hum Pathol 43:413-22. 2012
    ..Because IHC is recommended before gene amplification studies in HER2 testing, GCSS should be used for evaluating HER2 expression in gastric cancers...
  75. pmc Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study
    Dong Hoe Koo
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    BMC Cancer 11:205. 2011
    ..We sought to evaluate prognostic factors affecting overall survival (OS), and to investigate the role of palliative chemotherapy using propensity score-based weighting, in patients with advanced small bowel adenocarcinoma (SBA)...
  76. pmc Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Yung Jue Bang
    Department of Internal Medicine, Seoul National University College of Medicine, Yongon dong 28, Chongno Gu, Seoul, 110 799, Republic of Korea
    Invest New Drugs 29:1449-58. 2011
    ..This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy...
  77. doi request reprint Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery
    Dong Hoe Koo
    Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Oncology 80:208-13. 2011
    ..We evaluated prognostic factors affecting relapse-free survival (RFS) and overall survival (OS), and investigated the role of adjuvant chemotherapy in patients with small bowel adenocarcinoma (SBA)...
  78. ncbi request reprint Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial
    Yeul Hong Kim
    Department of Hemato Oncology, Korea University, College of Medicine, Seoul, Korea
    Jpn J Clin Oncol 37:501-8. 2007
    ..This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer...
  79. doi request reprint Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
    ....
  80. doi request reprint Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer
    Jeong Eun Kim
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Cancer Sci 102:1706-11. 2011
    ..Our data collectively indicate that MMR status is not effective as a single predictive marker for response to irinotecan-based chemotherapy in mCRC patients...
  81. doi request reprint Capecitabine in the treatment of advanced gastric cancer
    Jae Lyun Lee
    University of Ulsan College of Medicine, Division of Oncology, Department of Internal Medicine, Asan Medical Center, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, Korea
    Future Oncol 4:179-98. 2008
    ..Many promising biological agents are now being tested in Phase III trials, incorporating capecitabine combinations as control arms, in patients with advanced gastric cancer...
  82. ncbi request reprint Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis
    Jae Lyun Lee
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Gastroenterol Hepatol 23:811-6. 2008
    ..We report our efficacy and safety results of EE in clinical practice...
  83. ncbi request reprint A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer
    Dae Ho Lee
    Division of Oncology, Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea
    Clin Cancer Res 13:6182-6. 2007
    ..Furthermore, pharmacokinetics and preliminary antitumor activity against SCLC were evaluated...
  84. ncbi request reprint Extrapulmonary small cell carcinoma: single center experience with 61 patients
    Sung Sook Lee
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Acta Oncol 46:846-51. 2007
    ..Clinical trials are needed to define adequate treatment strategies for EPSCC...
  85. doi request reprint Palliative treatment of malignant gastric outlet obstructions with a large-diameter metallic stent: prospective preliminary study
    Jin Hyoung Kim
    Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 388 1, Poongnap 2dong, Songpa Gu, Seoul, 138 736, Korea
    J Vasc Interv Radiol 21:1125-8. 2010
    ..Large-diameter stent placement may be clinically effective in gastric outlet obstruction cases with a high risk of stent migration as a result of mild obstructions or unusual obstruction location...
  86. doi request reprint ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
    Min Hee Ryu
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Asanbyeongwon gil 86, Songpa Gu, Seoul 138 736, Korea
    Expert Rev Anticancer Ther 9:1745-51. 2009
    ..The purpose of this review is to summarize the ML17032 study, and to discuss the impact and implications of the results...
  87. ncbi request reprint Both-sided intra-atrial intracardiac metastases as the initial presentation of testicular seminoma
    Jae Cheol Jo
    Division of Oncology, Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea
    Jpn J Clin Oncol 37:463-8. 2007
    ..This is a rare case that presented with metastatic testicular seminoma involving both atria of heart and causing symptomatic obstruction of blood flow tract...
  88. doi request reprint Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
    Dong Jun Yoo
    Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea
    J Gastroenterol Hepatol 26:145-54. 2011
    ..We investigated the efficacy of TACE with/without systemic chemotherapy (s-chemo) in these patients...
  89. ncbi request reprint Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer
    Tae Won Kim
    Section of Hematology Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Acta Oncol 41:689-94. 2002
    ..2 months. The principal adverse event was neutropenia. The combination of gemcitabine, UFT, plus oral leucovorin shows significant antitumor activity and a beneficial clinical effect with an acceptable level of toxicity...
  90. doi request reprint Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
    Atsushi Ohtsu
    National Cancer Center, Hospital East, Kashiwa, Chiba, Japan
    J Clin Oncol 29:3968-76. 2011
    ....
  91. doi request reprint Primary central nervous system marginal zone B-cell lymphoma of the Basal Ganglia mimicking low-grade glioma: a case report and review of the literature
    Inkeun Park
    Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Clin Lymphoma Myeloma 8:305-8. 2008
    ..It is important to diagnose primary CNS MZBL correctly because it is curable without unnecessary invasive treatment in cases of localized disease...
  92. pmc Infarction and Perforation of the Small Intestine due to Tumor Emboli from Disseminated Rectal Cancer
    Jae Cheol Jo
    Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Gut Liver 2:130-2. 2008
    ..This extremely rare complication of rectal cancer resulted from ischemia and infarct caused by disseminated metastatic tumor emboli without direct invasion or mass formation...
  93. ncbi request reprint Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients
    Jin Hyoung Kim
    Departments of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, Korea
    Gastrointest Endosc 66:256-64. 2007
    ..Metallic stents are a therapeutic option for patients with malignant GI obstruction...
  94. doi request reprint Clinical impact of EUS-guided Trucut biopsy results on decision making for patients with gastric subepithelial tumors ≥ 2 cm in diameter
    Jeong Hoon Lee
    Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Gastrointest Endosc 74:1010-8. 2011
    ..However, the clinical impact of EUS-guided Trucut biopsy (EUS-TCB) data on decision making in patients with a gastric SET has not been assessed...
  95. doi request reprint Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck
    Cheolwon Suh
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    J Nucl Med 49:1783-9. 2008
    ..Therefore, we evaluated whether pretreatment 18F-FDG uptake was a predictor of survival in patients with ENKTL of the head and neck...
  96. ncbi request reprint Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang
    Yoon Koo Kang
    Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
    Drugs 67:611-2. 2007
  97. pmc Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients
    Jin Hee Ahn
    Division of Hematology Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Korean Med Sci 19:397-400. 2004
    ..In conclusion, alternative therapy may be one of the etiologies for abnormal LFT in breast cancer patients receiving adjuvant chemotherapy...
  98. pmc Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor
    Hawk Kim
    Division of Hematology Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Korean Med Sci 20:512-5. 2005
    ..This is the first report, to our knowledge, describing concurrent male gynecomastia and testicular hydrocele after imatinib treatment of a patient with GIST...
  99. ncbi request reprint Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases
    Jae Lyun Lee
    Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Pancreas 27:e18-22. 2003
  100. ncbi request reprint Primary malignant lymphoma of the breast: clinicopathological study of nine cases
    Yeon Hee Park
    Department of Internal Medicine, Korea Cancer Center Hospital, 215 4, Gongneung dong, Nowon Ku, Seoul 139 706, Korea
    Leuk Lymphoma 45:327-30. 2004
    ..All cases achieved complete remission, but median overall survival was 12 months, showing very poor prognosis irrespective of the type of treatment modality...
  101. ncbi request reprint Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients
    Sarah Park
    Shien Lab, National Cancer Center Hospital, Tokyo, Japan
    Breast Cancer Res Treat 99:9-17. 2006
    ....